In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as…
Continue Reading
News Source: medicalxpress.com
Leave a Reply